I obtained in 2004 a PhD in Pharmacology from the University of Toulouse. My research interest in the laboratory of Digestive Biology (INSERM U531) was to decipher the signaling pathways involved in the initiation of colon and pancreas cancers.
In 2005, I joined the laboratory of Jeffrey Settleman at the Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School, in Boston (USA) where I characterized the differential drug response of mutated EGFR in non-small cell lung cancer. In 2006, I moved to the Surgery Department of the University of Melbourne (Australia) where I identified the crucial role of gastrin precursors in the tumor-initiating capacity of CD133-positive colon cancer cells. In 2009, I have been recruited as a junior assistant professor (INSERM CRCN) to establish a research program aiming to identify therapeutic targets in colorectal cancer.
Since 2018, I lead a research group at the IRSD (Institut de Recherche en Santé Digestive) studying the interactions between the intestinal epithelium and the environment, either luminal or stromal. By combining morphological, functional, pharmacological and microfluidic approaches to 3D cell primocultures of colorectal organoids and fibroblasts, we study the interactions between the intestinal epithelium and the fibroblasts in the context of inflammatory bowel diseases and the risk of tumorigenesis.
Pour en apprendre davantage
CR1 INSERM, Institut de Recherche en Santé Digestive,
INSERM u1220, INRA u1416, Université Paul Sabatier, Ecole Nationale Vétérinaire de Toulouse, Toulouse.